Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neoplasms AND Hormone-refractory Prostate Adenocarcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Neoplasms AND Hormone-refractory Prostate Adenocarcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-000080-42 Sponsor Protocol Number: Keto1 Start Date*: 2008-03-15
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A Phase II study of Chetoconazolo in patients with Metastatic Hormone-Refractory Prostate Cancer. Pilot study
    Medical condition: Patients with advanced or metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029096 Neoplasm prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004295-37 Sponsor Protocol Number: 1-2003 Start Date*: 2005-08-26
    Sponsor Name:Finnish Uro-Oncological Group
    Full Title: A phase III trial comparing docetaxel every third week to biweekly docetaxel monotherapy in metastatic hormone refractory prostate cancer patients.
    Medical condition: Patients with metastatic hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001992-22 Sponsor Protocol Number: ADVANCE Start Date*: 2018-06-12
    Sponsor Name:University of Oxford
    Full Title: Phase II open label randomised safety and efficacy study of the viral vectored ChAd-MVA 5T4 vaccine in combination with PD-1 checkpoint blockade in low- or intermediate-risk localized or locally ad...
    Medical condition: Low- and intermediate-risk prostate cancer and advanced metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-003585-34 Sponsor Protocol Number: METRO Start Date*: 2006-08-28
    Sponsor Name:
    Full Title: WEEKLY DOCETAXEL COMBINED WITH DAILY ORAL LOW DOSES OF PREDNISONE AND CYCLOPHOSPHAMIDE IN HORMONE-REFRACTORY PROSTATE CARCINOMA A PHASE I/II STUDY
    Medical condition: hormone refractory prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036908 HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001192-39 Sponsor Protocol Number: P11-1 Start Date*: 2012-01-26
    Sponsor Name:Dendreon Corporation
    Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003224-38 Sponsor Protocol Number: D4320C00015 Start Date*: 2007-12-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer ...
    Medical condition: Hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) LV (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004405-30 Sponsor Protocol Number: ARN-AR18-CT-102 Start Date*: 2014-02-12
    Sponsor Name:Arno Therapeutics Inc
    Full Title: A Phase 1 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer
    Medical condition: Advanced Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005837-13 Sponsor Protocol Number: COU-AA-301 Start Date*: 2008-06-10
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Doceta...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Docetaxel-Based Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) DE (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021529-11 Sponsor Protocol Number: EMR62242-006 Start Date*: 2011-03-10
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II trial investigating two doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant pr...
    Medical condition: subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Prematurely Ended) NL (Completed) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003680-22 Sponsor Protocol Number: BC1-04 Start Date*: 2006-02-01
    Sponsor Name:Algeta ASA
    Full Title: A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases.
    Medical condition: Hormone refractory prostate cancer and skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    10060862
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005201-27 Sponsor Protocol Number: D361EC00001 Start Date*: 2022-06-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Cas...
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005251-25 Sponsor Protocol Number: CABACARE Start Date*: 2017-04-07
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, p...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004271-37 Sponsor Protocol Number: E7389-G000-204 Start Date*: 2006-01-20
    Sponsor Name:Eisai Limited
    Full Title: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemother...
    Medical condition: Advanced/metastatic hormone-refractory prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-022802-41 Sponsor Protocol Number: 3104001 Start Date*: 2011-02-25
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, MULTIPLE DOSE ESCALATION STUDY WITH A RANDOMISED PHASE I...
    Medical condition: Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002717-21 Sponsor Protocol Number: A4021011 Start Date*: 2006-07-27
    Sponsor Name:Pfizer Inc,235 East 42nd Street, New York,NY 10017
    Full Title: A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REF...
    Medical condition: Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002271-17 Sponsor Protocol Number: 9785-CL-0410 Start Date*: 2014-02-25
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
    Medical condition: Metastatic progressive castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002738-36 Sponsor Protocol Number: G-0029 Start Date*: 2005-11-08
    Sponsor Name:Cell Genesys Inc
    Full Title: A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10036909
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003811-23 Sponsor Protocol Number: ABIDO Start Date*: 2013-12-26
    Sponsor Name:SOGUG - Spanish Oncology Genitourinary Group
    Full Title: Abirateriona acetate maintenance in combination with docetaxel after disease progression to abiraterona acetate in metastatic castration resistant prostate cancer. Randomized phase II study.
    Medical condition: Metastatic castration resistant prostate cáncer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003192-28 Sponsor Protocol Number: SOG-MIE-2014-04 Start Date*: 2015-01-02
    Sponsor Name:SOGUG
    Full Title: Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS in response to enzalutamide in patients with metastatic CRPC no previously treated with chemotherapy
    Medical condition: Metastatic castration-resistant prostate cancer no previously treated with chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 09:38:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA